Loading company…
NovImmune develops monoclonal antibody therapies for autoimmune and immune-mediated conditions.
NovImmune researches and develops monoclonal antibodies for autoimmune diseases and other immune-mediated conditions. Founded in 1998, the company is based in Geneva, Switzerland, and is led by CEO Nicolas Fischer. In January 2016, it raised CHF 30 million from existing investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in